Experts Ola Landgren, Suzanne Lentzsch, Thomas Martin, and Suzanne Trudel discuss bone disease treatment in myeloma, updates with isatuximab and belantamab mafodotin, and the value of measurable residual disease (MRD) in clinical trials at the iwMyeloma 2024 session. Topics include bisphosphonates, sequencing strategies, drug approval, and the importance of data-sharing in myeloma research.

Dr. Ola Landgren discusses the rise of blood-based tests for myeloma care, highlighting the benefits of less invasive testing methods such as mass spectrometry, MRD testing, and circulating tumor cell testing. These tests offer a more comfortable and informative experience for patients and doctors, potentially replacing bone marrow biopsies. The podcast delves into the different types of blood-based tests, their functions, and how they could enhance myeloma practice in the future.

Experts from various institutions discuss Measurable Residual Disease (MRD) in the field of hemonc. They explore the role of MRD as a prognostic factor, novel technologies for MRD detection, and MRD measurement as a strategy for treatment-free survival. Recorded at several conferences, this podcast dives into the exciting realm of MRD in cancer management.